Clinical Trial Detail

NCT ID NCT02503709
Title Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

AT7519

Onalespib

Age Groups: adult

No variant requirements are available.